Advertisement
AZTA vs IQV
Which Stock Would AI Choose? Azenta, Inc. (AZTA) vs. IQVIA Holdings Inc. (IQV) Stock Comparison
Key Takeaways
- Both AZTA and IQV operate in the healthcare sector, with AZTA focusing on life sciences sample management tools and IQV providing clinical research and data analytics services.
- Recent market activity shows volatility for both, with AZTA experiencing sharp declines post-earnings miss and IQV rallying on strong quarterly results.
- IQV boasts a significantly larger market cap (~$30B vs. ~$1B for AZTA) and higher revenue scale ($16B+ TTM).
- Tickeron's comparison rates IQV as a stronger buy short- and long-term, supported by better technical scores.
- Analyst targets suggest upside potential for both, averaging $35+ for AZTA and $230 for IQV.
- AI trading bots on Tickeron highlight opportunities in healthcare-related sectors like semiconductors and data centers relevant to life sciences.
Introduction
This stock comparison examines AZTA and IQV, two players in the life sciences and healthcare sectors amid evolving market dynamics. Investors and traders analyzing relative performance in diagnostics, research tools, and clinical services may find value here. Recent earnings cycles and sector momentum have driven divergent price behaviors, offering insights into growth drivers, risks, and positioning. With healthcare innovation accelerating through AI and biotech advancements, understanding these contrasts aids portfolio allocation in a volatile environment focused on stock comparison and market positioning.
AZTA Overview and Recent Performance
Azenta, Inc. (AZTA) specializes in biological and chemical compound sample management solutions for the life sciences industry, including automated storage systems and genomic services. Headquartered in the U.S. with about 3,000 employees, it serves biotech and semiconductor clients globally. In recent market activity, AZTA shares have shown high volatility, rebounding from 52-week lows before sharp declines following Q2 fiscal 2026 earnings. Revenue reached $144.8 million, up slightly year-over-year but missing estimates, with adjusted EPS of -$0.04 versus expected +$0.14. This triggered a sell-off, influenced by operational challenges and uneven execution in life sciences spending. Sentiment reflects caution amid broader sector pressures, though analyst targets average $35.40, implying upside from current levels around $19.
IQV Overview and Recent Performance
IQVIA Holdings Inc. (IQV) delivers clinical research services, commercial insights, and healthcare intelligence to life sciences and healthcare firms worldwide. Operating through segments like Technology & Analytics Solutions (TAS), Research & Development Solutions (R&DS), and Contract Sales & Medical Solutions, it employs 93,000 people from its Durham, NC headquarters. Recent weeks saw IQV surge over 9% in a day on robust Q1 2026 results: revenue of $4.15 billion, up 8.4% year-over-year and beating estimates, with adjusted EPS of $2.90 topping forecasts. Growth in Commercial Solutions, fueled by AI integration, bolstered confidence, leading to reaffirmed full-year guidance. Despite YTD pressures, this performance has shifted sentiment positively, with shares trading near $177 and average analyst targets at $229.60.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases 25 top-performing AI trading bots, curated by AI analysis from over 351 total bots that trade thousands of tickers across diverse strategies, timeframes, and sectors. These bots excel in current market conditions, posting annualized returns from +23% to +169%, win rates of 51-88%, and profit factors up to 11.70. Examples include a volatility bot on energy tickers at +169% annualized (75% win rate) and leveraged ETF strategies exceeding +130%. With varying styles—from trend-following in semiconductors and industrials to short-term scalping in small-caps— they adapt to volatility in healthcare-adjacent areas like data centers and AI infrastructure. Traders can explore these high-conviction signals for enhanced decision-making.
Head-to-Head Comparison
AZTA and IQV share healthcare sector exposure but diverge in scale and models: AZTA's niche hardware focus contrasts IQV's broad services in clinical trials and analytics. Growth drivers differ—AZTA ties to biotech R&D capex, vulnerable to spending slowdowns, while IQV benefits from steady pharma demand and AI-enhanced insights. Recent momentum favors IQV post-earnings beat versus AZTA's miss, with Tickeron rating IQV higher technically (7 bullish signals). Risk profiles show AZTA's higher beta (1.43) amplifying volatility against IQV's stability (beta 1.18), though AZTA has lower debt. Market sentiment leans toward IQV's scale amid relative performance trade-offs.
Tickeron AI Verdict
Tickeron’s AI currently favors IQV over AZTA, driven by stronger trend consistency, earnings stability, and superior technical outlook in recent analyses. IQV's larger backlog ($34B+), AI catalysts, and relative positioning in diagnostics research provide higher probability of near-term outperformance, though AZTA offers value if life sciences rebound.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AZTA is a Hold and IQV is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 0 FA rating(s) are green whileIQV’s FA Score has 0 green FA rating(s).
- AZTA’s FA Score: 0 green, 5 red.
- IQV’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 5 TA indicator(s) are bullish while IQV’s TA Score has 6 bullish TA indicator(s).
- AZTA’s TA Score: 5 bullish, 5 bearish.
- IQV’s TA Score: 6 bullish, 3 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а -28.73% price change this week, while IQV (@Medical Specialties) price change was -0.77% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.67%. For the same industry, the average monthly price growth was +1.17%, and the average quarterly price growth was +21.59%.
The average weekly price growth across all stocks in the @Medical Specialties industry was -1.20%. For the same industry, the average monthly price growth was +0.09%, and the average quarterly price growth was -7.93%.
Reported Earning Dates
AZTA is expected to report earnings on Aug 11, 2026.
IQV is expected to report earnings on Jul 28, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.67% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical Specialties (-1.20% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| AZTA | IQV | AZTA / IQV | |
| Capitalization | 808M | 29.2B | 3% |
| EBITDA | 36.6M | 3.52B | 1% |
| Gain YTD | -47.264 | -22.337 | 212% |
| P/E Ratio | 42.43 | 21.75 | 195% |
| Revenue | 596M | 16.6B | 4% |
| Total Cash | 381M | 2.1B | 18% |
| Total Debt | 55.7M | 16.1B | 0% |
AZTA | IQV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 6 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 67 Overvalued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 42 | |
PRICE GROWTH RATING 1..100 | 92 | 58 | |
P/E GROWTH RATING 1..100 | 86 | 47 | |
SEASONALITY SCORE 1..100 | 17 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZTA's Valuation (67) in the Electronic Production Equipment industry is in the same range as IQV (67) in the Servicestothe Health Industry industry. This means that AZTA’s stock grew similarly to IQV’s over the last 12 months.
AZTA's Profit vs Risk Rating (100) in the Electronic Production Equipment industry is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that AZTA’s stock grew similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is somewhat better than the same rating for AZTA (93) in the Electronic Production Equipment industry. This means that IQV’s stock grew somewhat faster than AZTA’s over the last 12 months.
IQV's Price Growth Rating (58) in the Servicestothe Health Industry industry is somewhat better than the same rating for AZTA (92) in the Electronic Production Equipment industry. This means that IQV’s stock grew somewhat faster than AZTA’s over the last 12 months.
IQV's P/E Growth Rating (47) in the Servicestothe Health Industry industry is somewhat better than the same rating for AZTA (86) in the Electronic Production Equipment industry. This means that IQV’s stock grew somewhat faster than AZTA’s over the last 12 months.
| AZTA | IQV | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 77% | N/A |
| Stochastic ODDS (%) | 1 day ago 72% | 1 day ago 74% |
| Momentum ODDS (%) | 1 day ago 84% | 1 day ago 62% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 80% | 1 day ago 63% |
| TrendMonth ODDS (%) | 1 day ago 82% | 1 day ago 62% |
| Advances ODDS (%) | 6 days ago 70% | 6 days ago 58% |
| Declines ODDS (%) | 1 day ago 82% | 15 days ago 63% |
| BollingerBands ODDS (%) | 1 day ago 80% | 1 day ago 77% |
| Aroon ODDS (%) | 1 day ago 79% | 1 day ago 47% |
Advertisement